THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS

被引：0
|
作者：
Oh, Youjin [1 ]
Djunadi, Trie Arni [1 ]
Chung, Liam Il-Young [1 ]
Lee, Soowon [2 ]
Hong, Timothy [3 ]
Shah, Zunairah [1 ]
Park, Joo Hee [1 ]
Yoon, Sung Mi [1 ]
Duan, Richard [1 ]
Chae, Young Kwang [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Baylor Univ, Waco, TX USA
[3] Northwestern Univ, Evanston, IL USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.1413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1413
引用
收藏
页码：A1468 / A1469
页数：2
相关论文
共 50 条
  • [1] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [4] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Friedlander, Michael
    Marschner, Ian
    Simes, John
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST).
    Stillman, Ipek Ozer
    Strand, Lauren N.
    Chang, Jane
    Mohamed, Ateesha F.
    Fahrbach, Kyle
    Freier, Katherine E. Tranbarger
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] OVERALL SURVIVAL (OS) VERSUS PROGRESSION-FREE SURVIVAL (PFS): IS THERE A RATIONAL FOR REPLACING ONE OUTCOME FOR THE OTHER?
    Teich, V
    Fernandes, R. A.
    VALUE IN HEALTH, 2017, 20 (09) : A863 - A863
  • [8] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Examples of Population Kinetics (PopKin) Assessments of Progression-Free (PFS) and Overall Survival (OS)
    Stewart, D.
    Aljassim Alshareef, A.
    Robinson, A.
    Fung-Kee-Fung, M.
    Ong, M.
    Awan, A.
    Ocana, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1213 - S1213
  • [10] Correlation of circulating miRNA levels with progression-free survival (PFS) and overall survival (OS) in early-stage lung adenocarcinoma
    Grignani, Francesco
    Trombi, Riccardo
    Baglivo, Sara
    Gunnellini, Marco
    Di Carlo, Marinella
    Tofanetti, Francesca Romana
    Siggillino, Annamaria
    Metro, Giulio
    Bennati, Chiara
    Cagini, Lucio
    Puma, Francesco
    Pistola, Lorenza
    Chiari, Rita
    Ludovini, Vienna
    Crino, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345